Exercise reduced abdominal visceral fat, a risk factor for cardiometabolic disease, but not when obese patients received tocilizumab, an anti-arthritis drug that blocks IL-6 receptors, in a new study.
Medscape Medical News …read more
Exercise reduced abdominal visceral fat, a risk factor for cardiometabolic disease, but not when obese patients received tocilizumab, an anti-arthritis drug that blocks IL-6 receptors, in a new study.
Medscape Medical News …read more